Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L‐ASP: A retrospective analysis with an ASP‐based protocol in adult patients with acute lymphoblastic leukaemia
British Journal of Haematology · 2023
DOI: 10.1111/bjh.18683 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift British Journal of Haematology, 2023. Verfasst von RuiQi Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Venous Thromboembolism, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Venous thromboembolism (VTE) is a well‐known complication in patients with acute lymphoblastic leukaemia (ALL) receiving asparaginase (ASP)‐based chemotherapy, including the ASP‐intensive Dana‐Farber Cancer Institute (DFCI) 91–01 protocol for adults. Since 2019, native L‐ASP is no longer available in Canada and was replaced by pegylated (PEG)‐ASP. To determine whether the incidence of VTE has changed since switching from L‐ASP to PEG‐ASP, we conducted a single‐centred retrospective cohort study. We included 245 adult patients with Philadelphia chromosome negative ALL between 2011 and 2021, with 175 from the L‐ASP group (2011–2019) and 70 from the PEG‐ASP group (2018–2021). During Induction, 10.29% (18/175) of patients who received L‐ASP developed VTE, whereas 28.57% (20/70) of patients who received PEG‐ASP developed VTE ( p = 0.0035; odds ratio [OR] 3.35, 95% confidence interval [CI] 1.51–7.39), after adjusting for line type, gender, history of VTE, platelets at diagnosis. Similarly, during Intensification, 13.64% (18/132) of patients had VTE on L‐ASP while 34.37% (11/32) of patients on PEG‐ASP developed VTE ( p = 0.0096; OR 3.96, 95% CI 1.57–9.96 with multivariable analysis). We found that PEG‐ASP is associated with a higher incidence of VTE compared to L‐ASP, both during Induction and Intensification, despite the administration of prophylactic anticoagulation. Further VTE mitigation strategies are needed in particular for adult patients with ALL receiving PEG‐ASP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada.
ORCID-Profile: RuiQi Chen, Eshetu G Atenafu, Vikas Gupta, Dawn Maze, Hassan Sibai
Zitieren
APA
Chen, R., Atenafu, E. G., Seki, J., Liu, X., Chan, S., Gupta, V., Maze, D., Shuh, A. C., Minden, M. D., Yee, K., Schimmer, A. D., & Sibai, H. (2023). Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L‐ASP: A retrospective analysis with an ASP‐based protocol in adult patients with acute lymphoblastic leukaemia. British Journal of Haematology. https://doi.org/10.1111/bjh.18683
Vancouver
Chen R, Atenafu EG, Seki J, Liu X, Chan S, Gupta V, et al. Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L‐ASP: A retrospective analysis with an ASP‐based protocol in adult patients with acute lymphoblastic leukaemia. British Journal of Haematology. 2023. doi:10.1111/bjh.18683
BibTeX
@article{Chen2023,
author = {Chen, RuiQi and Atenafu, Eshetu G and Seki, Jack and Liu, Xing and Chan, Steven and Gupta, Vikas and Maze, Dawn and Shuh, Andre C and Minden, Mark D and Yee, Karen and Schimmer, Aaron D and Sibai, Hassan},
title = {Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L‐ASP: A retrospective analysis with an ASP‐based protocol in adult patients with acute lymphoblastic leukaemia},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.18683}
}
EUVIMED